Banque Cantonale Vaudoise’s Supernus Pharmaceuticals SUPN Stock Holding History

Banque Cantonale Vaudoise’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,787	Closed	-$58K	–	1354
2022 Q1	$58K	Hold	1,787	–	–	﹤0.01%	1015
2021 Q4	$52K	Hold	1,787	–	–	﹤0.01%	1064
2021 Q3	$48K	Buy	1,787 +700	+64%	+$18.8K	﹤0.01%	1053
2021 Q2	$33K	Buy	+1,087	New	+$33.3K	﹤0.01%	1103

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Banque Cantonale Vaudoise's SUPN Position: Q2 2022 in Review

Banque Cantonale Vaudoise sold out of Supernus Pharmaceuticals (SUPN) in Q2 2022, closing a stake of 1,787 shares — an estimated $58K sold.

Banque Cantonale Vaudoise first reported a position in SUPN in Q2 2021 and held it in 4 quarters. The position peaked at $58K in Q1 2022. 225 funds tracked by Wall St. Rank hold SUPN as of Q2 2022.

Banque Cantonale Vaudoise reported no remaining Supernus Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Banque Cantonale Vaudoise sold 1,787 Supernus Pharmaceuticals shares in Q2 2022, an estimated $58K.
Banque Cantonale Vaudoise first reported a position in Supernus Pharmaceuticals in Q2 2021 and held it in 4 quarters.
Banque Cantonale Vaudoise's Supernus Pharmaceuticals position peaked at $58K in Q1 2022.
225 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2022.

Based on Banque Cantonale Vaudoise's 13F filing for Q2 2022, filed 2 Aug 2022.